Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An investigational cell therapy consisting of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) being developed by the Arthritis Clinic & Research Center at Peking University People's Hospital. The therapy involves isolating MSCs from the Wharton's jelly of human umbilical cords and administering them via intra-articular injection into the knee joint. It is designed to treat knee osteoarthritis by leveraging the cells' ability to differentiate into chondrocytes for cartilage regeneration and their secretion of anti-inflammatory factors to modulate the joint environment and reduce pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Peking University People's Hospital).